MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
MAPS announced that its Phase 3 MDMA trial for PTSD is now fully enrolled at 13 sites across the United States and Israel.
The organization took equity initiatives to ensure that BIPOC and LGBTQ+ individuals are represented in the study, as these individuals are more likely to have PTSD (yet less likely to be diagnosed or have reasonable access to treatment).